Search results for
A biosimilar is a biologic therapeutic item which is duplicate of a unique item that is produced by an alternate organization. Biosimilars are authoritatively sanction forms of unique "discoverer" items, and can be produced when the first item's patent terminates. Reference to the pioneer item is a fundamental part of the approbation.
Biosimilar medicines are follow-on versions of original biological medicines. Biosimilars can be developed during the period in which the originator product is protected by patent exclusivity, but they can only be marketed after the patent protecting the originator product has expired.
Biosimilar medicines are independently developed to have the same mechanism of action as the original biological medicines, and are designed to treat the same diseases as the innovator’s product.
Related Journals of Biosimilars
Journal of Bioanalysis & Biomedicine, Enliven: Biosimilars and Bioavailablity, Journal of Bioequivalence & Bioavailability, MOJ Bioequivalence & Bioavailability, Bioequivalence Study Journal, Chemical Speciation & Bioavailability, International Journal of BioAnalytical Methods & BioEquivalence Studies, Asian Journal of Pharmaceutical & Biological Sciences, Bioanalytical Methods & Bioequivalence Studies, Pharmaceutical Regulatory Affairs: Open Access, Journal of Molecular Pharmaceutics & Organic Process Research.